Investing Accelerator Summit 🚀

Learn from the Sharpest Minds in Indian Investing Community 🚀

[Investing Accelerator Summit 🚀 @ias_summit]

30 investors. 20 stock ideas, 10 powerful investing frameworks, and 5 sessions with listed-company management.

Investing Accelerator Summit 2026 — live, Aug 7 & 8.

https://t.co/pxyVFDOJeT

Full lineup 👇

Vivek Mashrani · TechnoFunda Investing
Ishmohit Arora · SOIC
Tariq Hussain · The Wrap
Siddhant Bhandari · Persistence Capital
Kumar Saurabh · Scientific Investing
Amit Jeswani · Stallion Asset
Rohan Mehta · Turtle Wealth
Amitabh Vatsya · Sadhan
Puneet Khurana · Stoic Investment
Sagar Arya · Xponent Tribe
Nooresh Merani · NooreshTech
Digant Haria · GreenEdge Wealth
Prakash Diwan · Investor
Sanjay Kumar Elangovan · ithought PMS
Jiten Parmar · Aurum Capital
Vipin Agarwal · Turnaround Corporate Advisors
Lalit Rathi · LKR Advisors
Rajeev Agarwal · DoorDarshi Advisors
Ankit Kanodia · Zen Nivesh
Tushar Bohra · Invexa Capital
Priyam Shah · Trinetra Asset Managers
Gunjan Kabra · Niveshaay
Navy Ramavat · Indira Securities
Piyush Sarawagi · Agility Advisors
Abhinav Aggarwal · Fluid AI
Raghav Aggarwal · Fluid AI
Rushabh Doshi · Proinvest Nirmiti
D Prasad · Investor
Nitya Shah · Kamaya Kya

Join us live → https://t.co/pxyVFDOJeT

[Investing Accelerator Summit 🚀 @ias_summit]

https://t.co/aku59hPNT4

[CompoundingAI @compoundingaiin]

Performance of stock ideas from the IAS Summit Online 20-20 Edition (Dec 21, 2025), as of today:

1) 14 winners, 6 losers (20 picks)

2) Average return: +28.1% | Median: +5.7%

3) An equally weighted portfolio would have outperformed the Nifty 500 by 30%.

[Sudheer Kumar @GannamskKumar]

I'm attending the Investing Accelerator Summit 2026 📈 7–8 Aug, online & live.

Two days, thirty sessions — 20 company breakdowns, 5 masterclasses, 5 dialogues with listed-company managements. @ias_summit

Join me 👇 https://t.co/4HAdD6Waam https://t.co/gp7EImFc72

[Akshay Chhabra @CaptAkshayChh]

I'm attending the Investing Accelerator Summit 2026 📈 7–8 Aug, online & live.

Two days, thirty sessions — 20 company breakdowns, 5 masterclasses, 5 dialogues with listed-company managements. @ias_summit

Join me 👇 https://t.co/zDeYKORIpt https://t.co/ovmm9XQFc8

[Tar ⚡ @itsTarH]

Last year presented on $AMD at 150

Before that on Interarch Building at 1200 and Aarti Pharmalabs at demerger at 250ish

This time will present on a US business in the consumer space

See you all in Goa!

[Investing Accelerator Summit 🚀 @ias_summit]

@ashokku01926098 Hi. All details are at: https://t.co/iTuWvaRnyd

[Investing Accelerator Summit 🚀 @ias_summit]

30 investors. 20 stock ideas, 10 powerful investing frameworks, and 5 sessions with listed-company management.

Investing Accelerator Summit 2026 — live, Aug 7 & 8.

https://t.co/pxyVFDOJeT

Full lineup 👇

Vivek Mashrani · TechnoFunda Investing
Ishmohit Arora · SOIC
Tariq Hussain · The Wrap
Siddhant Bhandari · Persistence Capital
Kumar Saurabh · Scientific Investing
Amit Jeswani · Stallion Asset
Rohan Mehta · Turtle Wealth
Amitabh Vatsya · Sadhan
Puneet Khurana · Stoic Investment
Sagar Arya · Xponent Tribe
Nooresh Merani · NooreshTech
Digant Haria · GreenEdge Wealth
Prakash Diwan · Investor
Sanjay Kumar Elangovan · ithought PMS
Jiten Parmar · Aurum Capital
Vipin Agarwal · Turnaround Corporate Advisors
Lalit Rathi · LKR Advisors
Rajeev Agarwal · DoorDarshi Advisors
Ankit Kanodia · Zen Nivesh
Tushar Bohra · Invexa Capital
Priyam Shah · Trinetra Asset Managers
Gunjan Kabra · Niveshaay
Navy Ramavat · Indira Securities
Piyush Sarawagi · Agility Advisors
Abhinav Aggarwal · Fluid AI
Raghav Aggarwal · Fluid AI
Rushabh Doshi · Proinvest Nirmiti
D Prasad · Investor
Nitya Shah · Kamaya Kya

Join us live → https://t.co/pxyVFDOJeT

[Investing Accelerator Summit 🚀 @ias_summit]

@chiragsinghvi15 @niteen_india Hi. All details are at: https://t.co/iTuWvaRnyd

[Mindful Investor @amitabhvatsya]

Honoured to be invited as a speaker — thank you for the opportunity and trust. Excited to share insights from my journey and to connect with fellow investors. See you there. 🙏⚡️📈

[Jiten Parmar @jitenkparmar]

Happy to present at this event.

I always enjoy my time at IAS.

Looking forward to meet investors at the event.

[viral @viralimitless]

@ias_summit IAS 2026 is locked in for me — Aug 7 & 8. Pretty excited and looking forward to it; the lineup and the management sessions are the reason I keep coming back.

Details: https://t.co/LNbHbXGbJA

[Nitya Shah @KamayaKya @NityaShah2000]

Look forward to presenting at this esteemed event!

Thanks to @cautkarshpandey bhai for the opportunity 🙌🙏

[Tushar Bohra @tusharbohra]

Looking forward to presenting at IAS 2026. This will be the first time I will present at IAS. Should be a good 2 days of focused discussions and catching up with lot of friends

[Sekhar @LearningEleven]

Multi-baggers and the ₹100–1,000 Cr PAT Transition

if you run below query on Screener, you will get 250+ names.

Profit after tax > 100 AND
Profit after tax < 350 AND
Sales growth 5years median > 15

Some of your next 5x opportunities are sitting in that list!

Here is the backdrop:

Amit Jeswani (@Amit_Jeswani1) famously mentioned at an @ias_summit event a few years ago that most multi-baggers are created during the journey from ₹100 Cr to ₹1,000 Cr in PAT.

By the way, the next IAS Event is just about a month away! Keep a close eye on it - it's an annual ritual!

Coming back to our topic, a recent textbook example of this phenomenon was MCX.

MCX reported a PAT of ₹149 Cr in FY23, which dropped to ₹83 Cr in FY24, largely due to the technology contract issues that played villain during that phase.

Post those setbacks, the turnaround has been phenomenal: PAT jumped to ₹560 Cr in FY25, and in FY26, MCX has delivered ₹1332 Cr.

Unsurprisingly, the stock has delivered > ~10x returns over the last three years.

Another powerful example is Laurus Labs. Laurus already delivered disproportionate returns once during the 2019–2022 cycle, when PAT surged from ₹94 Cr to ₹984 Cr. That was followed by a downcycle, but the next upcycle clearly started from FY24 onwards.

PAT in FY24 stood at ₹162 Cr, and it reached ₹890 Cr by FY26. The stock has already turned into a multi-bagger again during this phase, and arguably, the journey is still far from over.

The real exercise, therefore, is simple but not easy: Identify companies currently in the ₹100–300 Cr PAT range and assess which among them have the management quality, scalability, balance sheet strength, and sectoral tailwinds to compound into a four-digit PAT business.

The hard truth is that nearly 80% of such companies may never get there, which is why this game is never easy. But the formula remains valid, and repeatedly proven.

But your real work begins with filtering those 250+ companies.

Good luck, India!

[Investing Accelerator Summit 🚀 @ias_summit]

@MashraniVivek @ishmohit1 @soicfinance @itsTarH @persistencecap @suru27 @Amit_Jeswani1 @rohanmehta_99 @amitabhvatsya @PuneetK009 @XponentTribe @nooreshtech @P_diwan @sanjaylangval @jitenkparmar @vipinaggarwaal @DigantHaria @lalitinvestor @kanodiaankit12 @ZenNivesh @rajeev_agr @tusharbohra @PriyamInvests @KabraGunjan @niveshaay @NavyRamavat @_PiyushSarawagi @abhinav_fluidai @aggarwalraghav @Rushabh_Analyst @dprasad1 @NityaShah2000

[Prince @AI_June26]

Lost my primary X account @AI_Feb21.

Secondary account to stay connected in the meantime.

Pls amplify this msg to help me reach my network till i get back of my account.

Thank you

@unseenvalue @_chartitude @InvestmentBook1 @suru27 @LearningEleven @ishmohit1 @Prakashplutus

[Investing Accelerator Summit 🚀 @ias_summit]

Locking it in

🗓️ 6 – 9 August 2026
📍 Alila Diwa, Goa

Block the dates.
Registrations open soon.

[Investing Accelerator Summit 🚀 @ias_summit]

Coming Soon...

[Niteen S Dharmawat, CFA @niteen_india]

When I presented Bank of India in the @ias_summit in Aug last year, at least 3 attendees later expressed their disappointment over the selection of the idea.
One of them was more direct and said, "PSU Banks kaun recommend karta hai, ye koi stock hai lene ke liye? Ye business-wise kabhi deliver nahi kar payenge."

Sometimes elephants dance... 🙂

[Sekhar @LearningEleven]

Timepass talk on Sunday

1. Time to Be a Small-Cap SIP Investor

Small-cap investors are completely squeezed. SMEs are facing a liquidity choke, and metals have suddenly grown Red Bull wings. Yet the age-old truth remains unchanged: small caps create disproportionate wealth when bought at reasonable valuations and held patiently until the tide turns.

That patience, however, demands a strong stomach, one that allows us to see a sea of red in the portfolio. If that isn’t your temperament, the safer route is simple: opt for small-cap funds. Any decently managed small-cap fund tends to deliver 70%+ returns within a year once the cycle turns.

Even ICICI Prudential Small Cap Fund, which had shut the doors to fresh inflows for nearly two years, is now saying, “Mutual Funds Sahi Hai."

So, if you’ve stayed invested through the pain, don’t quit now. Just ensure your stocks are falling because of market conditions, not because earnings visibility has collapsed.

The antithesis is equally important: Holding companies with no earnings visibility is dangerous, such names can permanently destroy capital, even take it to zero.

Conviction matters. So does discrimination.

2. Multi-baggers and the ₹100–1,000 Cr PAT Transition

Amit Jeswani (@Amit_Jeswani1) famously mentioned at an @ias_summit a few years ago that most multi-baggers are created during the journey from ₹100 Cr to ₹1,000 Cr in PAT.

A textbook example of this phenomenon today is MCX.

MCX reported a PAT of ₹149 Cr in FY23, which dropped to ₹83 Cr in FY24, largely due to the technology contract issues that played villain during that phase. Post those setbacks, the turnaround has been phenomenal: PAT jumped to ₹560 Cr in FY25, and for 9M FY26 itself, MCX has already delivered ₹801 Cr. The company is now well on track to cross ₹1,000 Cr PAT for the full year.

Unsurprisingly, the stock has delivered ~10x returns over the last three years.

Another powerful example is Laurus Labs. Laurus already delivered disproportionate returns once during the 2019–2022 cycle, when PAT surged from ₹94 Cr to ₹984 Cr. That was followed by a downcycle, but the next upcycle clearly started from FY24 onwards.

PAT in FY24 stood at ₹162 Cr, while the last four quarters have reported ₹233 Cr, ₹162 Cr, ₹194 Cr, and ₹252 Cr respectively. The stock has already turned into a multi-bagger again during this phase, and arguably, the journey is still far from over.

The real exercise, therefore, is simple but not easy: Identify companies currently in the ₹100–300 Cr PAT range and assess which among them have the management quality, scalability, balance sheet strength, and sectoral tailwinds to compound into a four-digit PAT business.

The hard truth is that nearly 80% of such companies may never get there, which is why this game is never easy. But the formula remains valid, and repeatedly proven.

3. MTF and the Recent Sell-off: A Reality Check

MTF has been the talk of the town lately, and some stocks may indeed have felt the pressure during the recent sell-offs. That said, when you actually run the numbers, the issue appears far less systemic than it has been portrayed.

Yes, the impact will vary from stock to stock, and a few names could see temporary stress. However, at the aggregate market level, the risk seems contained.

Consider this:

Out of 2,134 stocks with MTF exposure, ~83% can be fully unwound within ≤5 trading days based on average traded volumes.

The total MTF outstanding for these 83% names stands at approximately ₹91,000 Cr. The combined market capitalisation of these companies is around ₹382 lakh Cr. Put differently, MTF exposure is a small fraction of overall market value.

4. Hospitals Are Getting “Admitted” Too

In this sell-off, even hospitals, typically considered safe havens during brutal markets, haven’t been spared. Several leading names have seen meaningful corrections from recent highs:

Max Healthcare Institute: ~24%, Narayana Hrudayalaya: ~23%, Artemis Medicare Services: ~22%, HCG: ~21%, Apollo Hospitals: ~16%

Hospitals, of course, go through their own earnings cycles, largely driven by capacity additions and ramp-ups. That said, structurally, the sector remains a strong portfolio candidate for stable and consistent compounding, given predictable demand and improving operating leverage over time. Medical tourism from Bangladesh would have obviously slowed, but this should be more of a short-term blip.

At this stage, it may be worth evaluating how close these names are to their long-term median EV/EBITDA valuations. Any meaningful deviation below historical averages could start throwing up selective entry opportunities.

5. Menon Bearings

Menon Bearings delivered one of the strongest quarters in its history. Exports rose to an all-time high of ~36% of revenues, notably without any adverse impact from US tariffs. In its recent concall, management noted:

“…we have already started additional business with one of the major customers from the US… we hardly see any impact from the tariffs imposed by the USA. On the contrary, our exports are poised to grow further going ahead...”

For a company of this size, this is an interesting and positive development, especially in a challenging global environment.

That said, management also acknowledged that elevated copper prices are a margin headwind. While the company claims a pass-through mechanism, the timing and completeness of quarterly/monthly pass-throughs remain an open variable and need close monitoring.

From a cautionary standpoint, it’s worth recalling that in 2023 the company had articulated an ambition to double revenues by FY26. At the current run rate, the company appears far from that target, and it no longer seems to be a stated objective in the latest investor deck.

Nevertheless, a company executing well amid headwinds deserves a closer look.

6. Zydus Lifesciences - Zycubo (US$50 mn Peak Sales Opportunity)

Zycubo, a brand under Sentynl Therapeutics (a subsidiary of Zydus Lifesciences), has recently received approval from the U.S. Food and Drug Administration for the treatment of Menkes disease.

Menkes disease is an ultra-rare, life-threatening genetic disorder, diagnosed in newborns, with an estimated ~56 new cases annually in the US. If left untreated, median survival is less than 18 months.

Zycubo is the first and only FDA-approved therapy for this condition and has demonstrated meaningful survival benefits. In pivotal studies, when treatment was initiated early, within 10 days of birth, median survival extended to ~177 months, representing a step-change in clinical outcomes.

From a commercial standpoint, @SystematixGrp estimates price realisation at ~US$600,000 per patient per year. While affordability raises legitimate ethical and policy questions, Zycubo offers real hope to families with access through insurance or alternative funding.

7. Mackenna's Gold

Krishnadevaraya was the greatest ruler of the Vijayanagara Empire, presiding over an era of exceptional prosperity where gold, trade, and culture thrived at a civilisational peak. Legend has it that during his reign, gold and diamonds were so abundant that they were traded like grain.

That legacy seems to have quietly endured. Even today, Indian households are estimated to collectively hold ~34,600 tonnes of gold, one of the largest private gold stockpiles in the world. At $4,700 per ounce, this hoard is worth approximately $5.2 trillion.

For perspective, India’s GDP is about $3.7–4.0 trillion, while the total equity market capitalisation stands near $5.0–5.2 trillion.

Some civilisational habits don’t fade, they compound. The Jewellery companies and gold lenders are certainly trying to take advantage of it!

8. Defence Goes Global

On Jan 18, 2026, Rajnath Singh flagged off the first export consignment of guided Pinaka rockets from Solar Defence and Aerospace’s Nagpur facility. This marks the first export of the guided variant, following completion of unguided Pinaka deliveries by late 2024.

Armenia had earlier signed a ₹2,000 crore (US$250 mn) contract in 2022 for four Pinaka batteries, making it the first overseas customer for the Defence Research and Development Organisation (DRDO)-developed system. Pinaka offers precision strike capability up to 75 km (trialed up to 120 km).

This milestone reflects India’s defence export journey, from <₹1,000 crore a decade ago to ~₹24,000 crore today.

Globally, defence spending hit US$2.7 trillion in 2024, with 100+ countries increasing spends. With global tensions unlikely to ease soon, defence remains a structural, multi-year theme.

India, the world’s 5th-largest military spender with the 2nd-largest standing army, is uniquely positioned to benefit from this trend, both domestically and via exports.

From a market lens, the Motilal Oswal Nifty India Defence ETF (MODFENCE) is ~20% off recent highs and near a key support zone. Direction from here is uncertain, but with the Budget approaching, the theme is worth tracking closely.

9. Chemicals: Bottoming Out?

I came across a chart from Nuvama Research suggesting that both RoE and RoCE are likely at the bottom of the cycle after a sharp correction from FY22 peaks.

RoE declined from ~20.5% in FY22 to ~8.1% in FY25 and RoCE fell from ~23.2% to ~11.6% over the same period.

This compression reflects the severity of the chemical downcycle, weak demand, inventory destocking, and elevated costs.

At current levels (RoE ~8%, RoCE ~12%), return ratios are near the lower end of historical ranges. More importantly, the trend now points to stabilisation with marginal improvement, rather than further deterioration (of we course, we can never say never).

While a return to peak profitability will take time, the data suggests that most of the downside to returns has already played out, shifting the narrative toward gradual recovery and operating leverage.

Within this space, a few names I am actively tracking include:

📌Aether Industries – transitioning from a heavy capex phase to monetisation.

📌Acutaas – moving into a faster-growth CDMO phase.

📌Balaji Amines – positioning FY27 as a recovery year.

Each has a distinct playbook, and these are not a BUY or SELL recommendations.

10. DIIs & Retail Running Out of Gas?

Aggregate cash holdings of equity mutual funds have declined from ~7% in April 2025 to ~5.5% by December 2025, the lowest level since H1 2024.

Large-cap funds: ~6% → ~3.9%

Small-cap funds: ~9% → <6%

In simple terms, most funds are already fully invested. That limits incremental buying power from DIIs unless fresh inflows come in. Adding to the pressure, FPIs have already sold ~₹33,000 crore YTD.

With mutual fund cash buffers thin, market upside now depends more on new money and earnings, while corrections may feel sharper in the absence of dry powder.

The open question though: Can the Budget pull a rabbit out of the hat, via tweaks to LTCG, STCG, or STT, to revive FII participation? Or is that asking too much?

That’s all for today’s version. Happy Sunday!